COLGATE-PALMOLIVE COMPANY

2018A 2019A 2020A 2021A 2022A 2023E 2024E
Income Statement

Revenue 15,544.0 15,693.0 16,471.0 17,421.0 17,967.0 18,638.0 19,334.0
COGS 6,338.0 6,416.0 6,538.0 7,128.0 7,817.0 8,000.0 8,200.0
Gross Profit 9,206.0 9,277.0 9,933.0 10,293.0 10,150.0 10,638.0 11,134.0
SG&A expenses 5,356.0 5,515.0 6,022.0 6,407.0 6,565.0 6,762.0 6,897.0
Operating profit/EBIT 3,850.0 3,762.0 3,911.0 3,886.0 3,585.0 3,876.0 4,237.0
Other Income/Expenses
Non-operating Income/Expenses (92.0) (151.0) (122.0) (81.0) 46.0 (50.0) (60.0)
Non-operating Interest Income 50.0 47.0 19.0 17.0 14.0 15.0 16.0
Equity in Affiliates (Pretax) 10.0 9.0 12.0 12.0 12.0 12.0 12.0
Unusual Expense 161.0 174.0 13.0 630.0 830.0 850.0 870.0
Profit/(Loss) befoe interest and taxes 3,657.0 3,493.0 3,807.0 3,204.0 2,827.0 3,003.0 3,335.0
Interest Expense 193.0 192.0 160.0 117.0 167.0 170.0 175.0
Pretax income/EBT 3,464.0 3,301.0 3,647.0 3,087.0 2,660.0 2,833.0 3,160.0
Income Tax Income/(Expense)(Average) 906.0 774.0 787.0 749.0 693.0 700.0 710.0
Consolidated Net Income 2,558.0 2,527.0 2,860.0 2,338.0 1,967.0 2,133.0 2,450.0
Minority Interest Expense 158.0 160.0 165.0 172.0 182.0 190.0 200.0
Net Income 2,400.0 2,367.0 2,695.0 2,166.0 1,785.0 1,943.0 2,250.0


Balance Sheet

Assets
Cash and cash equivalents 726.0 883.0 888.0 832.0 775.0 800.0 825.0
Accounts Receivable 1,400.0 1,440.0 1,264.0 1,297.0 1,504.0 1,491.0 1,546.7
Inventories 1,250.0 1,400.0 1,673.0 1,692.0 2,074.0 1,863.0 1,797.3
Other Current Assets 417.0 456.0 513.0 576.0 760.0 820.1 869.0
Total Current Assets 3,793.0 4,179.0 4,338.0 4,397.0 5,113.0 4,974.2 5,038.0
Property, Plant & Equipment,net 3,881.0 3,750.0 3,716.0 3,730.0 4,307.0 5,050.0 5,500.0
Goodwill and other Intangible Assets 4,167.0 6,175.0 6,718.0 5,746.0 5,272.0 5,017.0 4,908.2
Other non-current assets
Differed Taxes 152.0 177.0 291.0 193.0 135.0 129.0 124.4
Other assets 168.0 753.0 857.0 974.0 904.0 950.0 980.0
Total Assets 12,161.0 15,034.0 15,920.0 15,040.0 15,731.0 16,120.2 16,550.6
Liabilities
current liabilities
Short-term debt 12.0 405.0 395.0 176.0 119.0 130.0 140.0
Current portion of long-term debt 254.0 9.0 12.0 14.0 15.0 17.0
Accounts Payable 1,222.0 1,237.0 1,393.0 1,479.0 1,551.0 1,600.0 1,650.0
Income tax payable 411.0 370.0 403.0 436.0 317.0 280.0 290.0
Other current liabilities/Accruals 1,696.0 1,772.0 2,204.0 1,948.0 2,003.0 2,133.2 2,271.9
Total Current Liabilities 3,341.0 4,038.0 4,404.0 4,051.0 4,004.0 4,158.2 4,368.9
Long-term Debt 6,354.0 7,824.0 7,810.0 7,645.0 9,138.0 9,357.7 9,582.3
Provision for Risks and Charges 1,600.0 1,743.0 1,825.0 1,724.0 1,129.0 1,095.1 1,062.3
Deferred taxes-credit 235.0 507.0 426.0 395.0 383.0 389.2 389.2
Other Liabilities 434.0 364.0 354.0 254.0 271.0 250.0 213.0
Total Liabilities 11,964.0 14,476.0 14,819.0 14,069.0 14,925.0 15,250.2 15,615.6
Shareholder’s Equity
Equity Capital (102.0) 117.0 743.0 609.0 401.0 450.0 500.0
Accumulated Minority Interest 299.0 441.0 358.0 362.0 405.0 420.0 435.0
Total Shareholder’s Equity 197.0 558.0 1,101.0 971.0 806.0 870.0 935.0
Total Liabilities & Shareholder’s Equity 12,161.0 15,034.0 15,920.0 15,040.0 15,731.0 16,120.2 16,550.6


Cash Flow Statement

Operating Cash Flow
Net Income including non-controlling interest 2,558.0 2,527.0 2,860.0 2,338.0 1,967.0 2,133.0 2,450.0
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations:
Depreciation, Depletion & Amortization 511.0 519.0 539.0 556.0 545.0 578.0 599.0
Gain/Loss On Sale of PPE 0.0 0.0 0.0 (47.0) 0.0 0.0
Loss on early extinguishment of debt 0.0 23.0 75.0 0.0 0.0 0.0
Pension and employee benefit expense (67.0) (113.0) 0.0 0.0 0.0 0.0 0.0
Deffered tax 27.0 17.0 (120.0) (132.0) (78.0) (78.0) (78.0)
Asset Impairment charge 0.0 0.0 571.0 721.0 721.0 721.0
Stock-based compensation 109.0 100.0 107.0 135.0 125.0 112.0 116.0
Other non-cash items/Restructuring and termination benefits, net of cash (7.0) 18.0 (71.0) (21.0) 49.0 49.0 49.0
Charge for U.S tax reform 80.0
Changes in Working Capital (155.0) 65.0 381.0 (197.0) (726.0) (796.0) (70.0)
Cash from Operations 3,056.0 3,133.0 3,719.0 3,325.0 2,556.0 2,719.0 3,787.0
Investing Cash Flow
Capital expenditures (436.0) (335.0) (410.0) (567.0) (696.0) (731.0) (766.0)
Purchases of marketable securities and investments 1.0 1.0 (143.0) (141.0) (470.0) (490.0) (508.0)
Proceeds from sale of marketable securities and investments (169.0) (184.0) 124.0 141.0 322.0 335.0 341.0
Payment for acquisitions, net of cash acquired 156.0 131.0 (353.0) 0.0 (809.0) (840.0) (875.0)
Proceeds from the sale of land (728.0) (1,711.0) 0.0 0.0 47.0 50.0 55.0
Other investing activities 6.0 (1.0) 3.0 (25.0) 5.0 5.0 5.0
cash from investing (1,170.0) (2,099.0) (779.0) (592.0) (1,601.0) (1,671.0) (1,748.0)
Financing Cash Flow
Short-term borrowing (repayment) less than 90 days, net 488.0 (171.0) 540.0 550.0 384.0
Principal payments on debt (7,355.0) (6,611.0) (1,085.0) (703.0) (406.0) (420.0) (1,000.0)
Proceeds from issuance of debt 7,176.0 8,059.0 699.0 1,513.0 1,550.0 1,000.0
Dividends paid (1,591.0) (1,614.0) (1,654.0) (1,679.0) (1,691.0) (1,700.0) (1,800.0)
Purchases of treasury shares (1,238.0) (1,202.0) (1,476.0) (1,320.0) (1,308.0) (1,350.0) (1,400.0)
Proceeds from exercise of stock options 329.0 498.0 874.0 424.0 418.0 430.0 440.0
Purchases of non-controlling interest in subsidiaries (99.0)
Other financing activities 33.0 (24.0) (18.0) (18.0) (18.0)
Cash from Financing (2,679.0) (870.0) (2,919.0) (2,774.0) (952.0) (958.0) (2,394.0)
Effect of exchange rate changes on Cash and cash equivalents (16.0) (7.0) (16.0) (15.0) (60.0) (65.0) (70.0)
Net Increase (decrease) in Cash or cash equivalents (809.0) 157.0 5.0 (56.0) (57.0) 25.0 (425.0)
Opening Cash Balance 1,535.0 726.0 883.0 888.0 832.0 775.0 1,250.0
closing cash balance 726.0 883.0 888.0 832.0 775.0 800.0 825.0

Based on the historical financial data in the income statement, balance sheet and cash flow statement from 2018 to 2022, what assumptions might the Colgate-Palmolive Company have made to forecast each line item for the period 2023 and 2024? provide me answer to this question for each line item in each of the financial statement on how those assumptions are consistent with the each line items' estimated figures in the forecasting period 2023 and 2024.